SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 198 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $23,319 | -41.7% | 13,249 | +4.0% | 0.00% | -60.0% |
| Q4 2022 | $39,985 | +471.2% | 12,734 | +848.9% | 0.01% | +400.0% |
| Q3 2022 | $7,000 | -56.2% | 1,342 | -65.5% | 0.00% | -50.0% |
| Q2 2022 | $16,000 | +1500.0% | 3,892 | +2287.7% | 0.00% | – |
| Q1 2022 | $1,000 | – | 163 | +83.1% | 0.00% | – |
| Q1 2020 | $0 | – | 89 | +50.8% | 0.00% | – |
| Q4 2019 | $0 | – | 59 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 59 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | – | 59 | 0.0% | 0.00% | – |
| Q1 2019 | $0 | – | 59 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 59 | 0.0% | 0.00% | – |
| Q3 2018 | $1,000 | – | 59 | 0.0% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 59 | -88.5% | 0.00% | -100.0% |
| Q1 2018 | $9,000 | +12.5% | 514 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $8,000 | +14.3% | 514 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $7,000 | +75.0% | 514 | 0.0% | 0.00% | +50.0% |
| Q2 2017 | $4,000 | +100.0% | 514 | 0.0% | 0.00% | +100.0% |
| Q1 2017 | $2,000 | – | 514 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alexandria Capital, LLC | 916,153 | $8,740,000 | 1.27% |
| Casdin Capital, LLC | 1,080,000 | $10,303,000 | 1.13% |
| Rhenman & Partners Asset Management AB | 843,957 | $8,051,000 | 0.94% |
| WASATCH ADVISORS LP | 6,437,908 | $61,418,000 | 0.67% |
| BB BIOTECH AG | 2,650,000 | $25,281,000 | 0.64% |
| Trellus Management Company, LLC | 30,000 | $286,000 | 0.54% |
| Opus Point Partners Management, LLC | 33,529 | $320,000 | 0.43% |
| SECTOR GAMMA AS | 238,857 | $2,279,000 | 0.36% |
| Leisure Capital Management | 37,656 | $359,000 | 0.30% |
| Ceeto Capital Group, LLC | 41,000 | $391,000 | 0.29% |